ADNP Kids Research Foundation
  • About
  • RESEARCH
    • Research Update 2.2024
    • ADNP Patient Registry & Natural History
    • Research Projects 2023
    • Research Strategy
    • Ketamine Trial
    • Ketamine Trial Publication
    • Ketamine Update
  • FAMILIES
  • NEWS
    • Giving Tuesday
    • NET Collaboration Study
    • Ketamine Trial Phase 2 Announcement >
      • Glimpse of Hope RDD 2020
    • Mount Sinai Launches First Drug Trial for ADNP Syndrome
    • Seaver Midtown Partnership
    • Biomarker Discovered
    • NEWS - p.Tyr719* Case Study
    • NEWS HIGHLIGHTS- ADNP Syndrome Family Conference
  • DONATE/SUPPORT
    • Warrior Fun Run >
      • Past Fun Run Pictures
      • Sponsorship Opportunity
    • Third Party Fundraising
    • ADNP STORE
  • contact us
  • ADNP STORE

Understanding
High Throughput
​Drug Screening

High throughput drug screening (HTS) is a powerful tool that can be used to identify potential drug candidates for rare neurological diseases. These diseases often have limited treatment options, and the development of new therapies can be challenging due to the small patient population and the complexity of the underlying disease mechanisms.

HTS involves the rapid screening of large libraries of compounds for their ability to interact with disease-specific targets or pathways. The screening process can be automated and scaled up to test hundreds of thousands or even millions of compounds in a short period of time.
To perform HTS for rare neurological diseases, researchers can use a variety of platforms, such as cell-based assays or biochemical assays, depending on the specific disease mechanism being targeted. For example, for diseases caused by mutations in ion channels, researchers may use electrophysiological assays to test the ability of compounds to modulate ion channel activity.
​
One advantage of HTS is that it can identify new drug candidates for rare neurological diseases that may not have been previously considered. However, it is important to validate any hits identified in HTS with additional experiments to ensure that they are safe and effective for use in humans.
Overall, HTS can be a valuable tool for identifying new therapeutic options for rare neurological diseases, and it has the potential to accelerate the drug discovery process for these challenging conditions.

The video below is with Dr. Chris Austin with the National Institutes of Health (NIH) showing their drug screening process.
Picture
Picture
Privacy Policy  |  Terms of Services  |  Other Policies  
All rights reserved. No portion of the content of this website may be reproduced in any manner without the written permission of the author/creator.   Any information used from this website must also have credit noted to ADNP Kids Research Foundation / www.adnpfoundation.org.
Disclosure: This page represents information known to the best of our knowledge.  Given the sensitivity and fast changing pace of research and drug development, some of the information posted on our website www.adnpfoundation.org may be inaccurate or not complete, therefor this information should be confirmed by the reader. Additionally, the medical information on this website is not substitute for personal diagnosis or medical care advise. Families and patients should consult a medically qualified clinician in all matters relating to genetic diagnosis, disease management and health. Information on ADNP research is a very fast-moving field and while the information here is believed to be the best available at the time of publication, some facts may later be updated or change. Please see additional disclosures on our PRIVACY POLICY page.
  • About
  • RESEARCH
    • Research Update 2.2024
    • ADNP Patient Registry & Natural History
    • Research Projects 2023
    • Research Strategy
    • Ketamine Trial
    • Ketamine Trial Publication
    • Ketamine Update
  • FAMILIES
  • NEWS
    • Giving Tuesday
    • NET Collaboration Study
    • Ketamine Trial Phase 2 Announcement >
      • Glimpse of Hope RDD 2020
    • Mount Sinai Launches First Drug Trial for ADNP Syndrome
    • Seaver Midtown Partnership
    • Biomarker Discovered
    • NEWS - p.Tyr719* Case Study
    • NEWS HIGHLIGHTS- ADNP Syndrome Family Conference
  • DONATE/SUPPORT
    • Warrior Fun Run >
      • Past Fun Run Pictures
      • Sponsorship Opportunity
    • Third Party Fundraising
    • ADNP STORE
  • contact us
  • ADNP STORE